# Lecture 11: Laboratory Medicine

## Unit 2.11: Pathology

---

## Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the principles of clinical laboratory testing
2. Explain the interpretation of common blood tests
3. Describe urinalysis and its clinical applications
4. Explain coagulation testing
5. Describe serologic testing methods
6. Explain molecular diagnostics and their applications

---

## Lecture Outline

### I. Principles of Laboratory Medicine

The accuracy and clinical utility of laboratory results depend critically on pre-analytical variables, the factors that influence a specimen before it reaches the analytical instrument. Patient preparation encompasses fasting requirements for glucose and lipid panels, timing of specimen collection relative to medication dosing for drug levels, and avoidance of strenuous exercise that may elevate muscle enzymes. Specimen collection requires proper technique, including correct order of draw for blood tubes to prevent additive contamination, appropriate tourniquet time to avoid hemoconcentration, and selection of the correct tube type for the intended assay. Specimen handling after collection demands attention to temperature, as some analytes are labile at room temperature, and processing time, since delays in separating serum from cells may allow continued cellular metabolism to alter results. Correct patient identification through proper labeling at the bedside is perhaps the most critical pre-analytical variable, as mislabeled specimens can lead to catastrophic errors such as ABO-incompatible transfusions. Transport conditions, including maintenance of appropriate temperature and protection from light exposure for light-sensitive analytes, must be maintained throughout the journey from collection to analysis.

The clinical value of any laboratory test is defined by its operating characteristics, statistical measures that quantify how well the test distinguishes between diseased and non-diseased individuals. Sensitivity, calculated as the number of true positives divided by the sum of true positives and false negatives, measures the test's ability to correctly identify individuals who have the disease, with a highly sensitive test producing few missed cases. Specificity, calculated as the number of true negatives divided by the sum of true negatives and false positives, measures the test's ability to correctly identify individuals who do not have the disease, with a highly specific test producing few false alarms. Positive predictive value (PPV), calculated as true positives divided by the sum of true positives and false positives, represents the probability that a positive test result reflects true disease and is heavily influenced by disease prevalence. Negative predictive value (NPV), calculated as true negatives divided by the sum of true negatives and false negatives, represents the probability that a negative result reflects true absence of disease. Accuracy, calculated as the sum of true positives and true negatives divided by the total number of tests, provides an overall measure of correct classifications.

Reference ranges and clinical decision levels provide the framework for interpreting laboratory results in clinical practice. The normal or reference range is established by testing a large population of healthy individuals and typically encompasses the central 95% of values, meaning that 2.5% of healthy individuals will have results above and 2.5% below the reference range by statistical definition alone. Critical values are results so abnormal that they may represent immediately life-threatening conditions requiring urgent clinical notification, such as a potassium above 6.5 mEq/L or a glucose below 40 mg/dL. Clinical decision levels represent thresholds at which specific clinical actions are triggered, such as initiating statin therapy at a particular LDL cholesterol level. Delta checks compare a patient's current result with their previous values, flagging significant changes that may indicate either genuine clinical deterioration or specimen error.

Quality control and quality assurance programs ensure that laboratory results are accurate and reliable. Internal quality control involves running control materials with known analyte concentrations alongside patient samples on a daily basis, monitoring precision through statistical tracking of control results using Levey-Jennings charts and Westgard rules that detect systematic and random errors. External quality assurance, also known as proficiency testing, involves analyzing unknown samples distributed by accrediting agencies and comparing results with those of other laboratories using the same methodology, providing an independent assessment of accuracy. Calibration standardizes the analytical system by establishing the relationship between measured signal and analyte concentration using materials with assigned values traceable to reference standards. Validation of new methods requires demonstration that the assay performs within acceptable limits for precision, accuracy, linearity, and clinical utility before it is introduced into routine patient testing.

<image>Panel A: Pre-analytical variables affecting test accuracy including patient preparation (fasting, medication timing), specimen collection technique, proper labeling, transport conditions, and processing time considerations. Panel B: Test characteristics illustrated with 2x2 contingency table showing sensitivity (TP/TP+FN), specificity (TN/TN+FP), positive predictive value, and negative predictive value calculations with clinical examples. Panel C: Reference range determination showing bell curve distribution with 95% of healthy population values, critical values requiring immediate notification, and clinical decision levels guiding treatment. Panel D: Quality control program showing internal daily controls for precision monitoring, external proficiency testing for accuracy verification, and calibration procedures for standardization.</image>

---

### II. Complete Blood Count

The complete blood count (CBC) is the most commonly ordered laboratory test and provides essential information about the three major cell lines produced by the bone marrow. The white blood cell (WBC) count normally ranges from 4,500 to 11,000 per microliter and reflects the balance between bone marrow production and peripheral consumption or destruction. The red blood cell (RBC) count normally ranges from 4.5 to 5.5 million per microliter in males and 4.0 to 5.0 million per microliter in females, with gender differences reflecting the stimulatory effect of androgens on erythropoiesis. Hemoglobin, the oxygen-carrying protein within red blood cells, normally measures 13.5 to 17.5 g/dL in males and 12.0 to 16.0 g/dL in females, and represents the most commonly used parameter for defining anemia. Hematocrit, the percentage of blood volume occupied by red blood cells, normally ranges from 38 to 50% in males and 36 to 44% in females. The platelet count normally ranges from 150,000 to 400,000 per microliter and reflects the balance between thrombopoiesis in the bone marrow and platelet consumption in hemostasis.

Red blood cell indices provide critical information about erythrocyte size and hemoglobin content that guides the classification and differential diagnosis of anemia. The mean corpuscular volume (MCV), calculated as hematocrit divided by the red blood cell count multiplied by 10, measures the average red blood cell size in femtoliters and serves as the primary basis for classifying anemias as microcytic, normocytic, or macrocytic. The mean corpuscular hemoglobin (MCH), calculated as hemoglobin divided by the red blood cell count multiplied by 10, quantifies the average amount of hemoglobin per red blood cell in picograms. The mean corpuscular hemoglobin concentration (MCHC), calculated as hemoglobin divided by hematocrit multiplied by 100, expresses the average hemoglobin concentration within red blood cells and is useful for identifying hyperchromic conditions such as hereditary spherocytosis. The red cell distribution width (RDW) quantifies the degree of variation in red blood cell size, with an elevated value indicating anisocytosis that may help distinguish iron deficiency anemia (high RDW) from thalassemia trait (normal RDW), both of which produce microcytic anemia.

The white blood cell differential quantifies the proportion and absolute count of each leukocyte subtype, providing diagnostic information that extends well beyond the total WBC count. Neutrophils normally constitute 40 to 70% of circulating leukocytes with an absolute count of 1,800 to 7,700 per microliter, and elevations (neutrophilia) typically indicate bacterial infection, while decreases (neutropenia) create susceptibility to infections. Lymphocytes represent 20 to 40% of leukocytes with an absolute count of 1,000 to 4,800 per microliter, and their proportion increases in viral infections and lymphoproliferative disorders. Monocytes account for 2 to 8% with absolute counts of 80 to 880 per microliter, and monocytosis may accompany chronic infections and certain malignancies. Eosinophils constitute 1 to 4% with absolute counts of 45 to 440 per microliter, and eosinophilia characteristically occurs with parasitic infections, allergic conditions, and certain malignancies. Basophils are the rarest circulating leukocytes at 0 to 1% with absolute counts of 0 to 110 per microliter, and basophilia may suggest a myeloproliferative neoplasm.

The peripheral blood smear provides morphologic information that automated analyzers cannot fully capture, making it an essential complement to the CBC in many clinical situations. Target cells, with their characteristic bull's-eye appearance, are associated with liver disease, hemoglobinopathies including thalassemia, and post-splenectomy states. Schistocytes, fragmented red blood cells with helmet or triangular shapes, are the hallmark of microangiopathic hemolytic anemia as seen in thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and disseminated intravascular coagulation. Spherocytes, small dense cells lacking central pallor, characterize hereditary spherocytosis and autoimmune hemolytic anemia (AIHA), reflecting loss of membrane surface area relative to cell volume. Howell-Jolly bodies, nuclear remnants within red blood cells that would normally be removed by the spleen, indicate functional or anatomic asplenia. Basophilic stippling, composed of precipitated ribosomal RNA fragments visible as fine blue dots throughout the red cell cytoplasm, is associated with lead poisoning and thalassemia, reflecting impaired ribosomal degradation.

<image>Panel A: Complete blood count components showing normal ranges for WBC, RBC, hemoglobin, hematocrit, and platelets with red cell indices (MCV for size, MCH for hemoglobin content, MCHC for concentration, RDW for variation). Panel B: White blood cell differential with normal percentages and absolute counts for neutrophils, lymphocytes, monocytes, eosinophils, and basophils, and clinical conditions causing shifts. Panel C: Peripheral blood smear interpretation showing target cells (liver disease, thalassemia), schistocytes (microangiopathic hemolysis), spherocytes (hereditary spherocytosis, AIHA), and Howell-Jolly bodies (asplenia). Panel D: Anemia classification by MCV showing microcytic causes (iron deficiency, thalassemia), normocytic causes (chronic disease, hemolysis), and macrocytic causes (B12/folate deficiency, MDS).</image>

---

### III. Chemistry Panel

The basic metabolic panel (BMP) provides essential information about electrolyte balance, renal function, and glucose homeostasis, forming the foundation of clinical chemistry assessment. Sodium, with a normal range of 136 to 145 mEq/L, is the primary determinant of extracellular fluid osmolality and reflects the balance between water intake, renal excretion, and hormonal regulation by antidiuretic hormone and aldosterone. Potassium, normally 3.5 to 5.0 mEq/L, is critical for cardiac and neuromuscular function, with both hypo- and hyperkalemia producing potentially fatal cardiac arrhythmias that make potassium a frequent critical value. Chloride, ranging from 98 to 106 mEq/L, typically tracks with sodium and is essential for acid-base balance, with its relationship to bicarbonate helping to identify the cause of metabolic acidosis. Carbon dioxide (CO2), reflecting serum bicarbonate at 23 to 29 mEq/L, provides a rapid assessment of acid-base status. Blood urea nitrogen (BUN), normally 7 to 20 mg/dL, and creatinine, normally 0.7 to 1.3 mg/dL, together assess renal function, though each has limitations. Fasting glucose, normally 70 to 100 mg/dL, serves as the primary screening and monitoring test for diabetes mellitus.

The comprehensive metabolic panel (CMP) adds hepatic function tests, protein levels, and calcium to the basic metabolic panel, providing a broader assessment of organ function. Calcium, normally 8.5 to 10.5 mg/dL, reflects the balance between parathyroid hormone, vitamin D, and calcitonin regulation and must be interpreted in the context of albumin levels since approximately 40% of circulating calcium is protein-bound. Total protein, ranging from 6.0 to 8.3 g/dL, and albumin, ranging from 3.5 to 5.5 g/dL, reflect hepatic synthetic capacity and nutritional status, with hypoalbuminemia occurring in liver disease, nephrotic syndrome, and malnutrition. Total bilirubin, normally 0.1 to 1.2 mg/dL, reflects the balance between heme catabolism, hepatic conjugation, and biliary excretion. Aspartate aminotransferase (AST), normally 10 to 40 U/L, and alanine aminotransferase (ALT), normally 7 to 56 U/L, are released from damaged hepatocytes and serve as markers of hepatocellular injury. Alkaline phosphatase, normally 44 to 147 U/L, is elevated in cholestatic liver disease, bone disease, and during normal growth in children.

Liver function tests are interpreted according to characteristic patterns that help identify the underlying pathologic process. The hepatocellular pattern demonstrates markedly elevated aminotransferases (AST and ALT) with relatively modest elevation of alkaline phosphatase, a pattern seen in viral hepatitis, drug-induced hepatotoxicity, and ischemic hepatitis, where direct hepatocyte damage releases intracellular enzymes into the circulation. The cholestatic pattern shows markedly elevated alkaline phosphatase and bilirubin with relatively mild transaminase elevation, indicating bile duct obstruction or intrahepatic cholestasis from gallstones, tumors, or drug reactions. The infiltrative pattern produces a moderate alkaline phosphatase elevation with relatively mild transaminase increases, as seen with granulomatous diseases and metastatic deposits in the liver. The ratio of AST to ALT provides additional diagnostic information, with an AST-to-ALT ratio greater than 2:1 strongly suggesting alcoholic liver disease, reflecting the combined effects of mitochondrial injury releasing AST and alcohol-mediated depletion of pyridoxal phosphate required for ALT synthesis.

Renal function tests provide complementary information about glomerular filtration and tubular function. Blood urea nitrogen (BUN) reflects both the production of urea from protein metabolism and its renal excretion, but is affected by dietary protein intake, gastrointestinal bleeding, catabolic states, and hydration status, limiting its specificity as a renal marker. Creatinine is produced at a relatively constant rate from muscle creatine metabolism and is freely filtered by the glomerulus with minimal tubular secretion, making it a more reliable marker of glomerular filtration, though it is influenced by muscle mass, producing lower baseline values in elderly and cachectic patients. The estimated glomerular filtration rate (eGFR), calculated from serum creatinine using equations that account for age, sex, and race, provides the best overall estimate of kidney function and is used to stage chronic kidney disease. The BUN-to-creatinine ratio helps distinguish pre-renal azotemia, in which the ratio exceeds 20:1 due to enhanced urea reabsorption in the dehydrated state, from intrinsic renal disease where the ratio remains in the normal range of 10-20:1. Cystatin C, a small protein produced at a constant rate by all nucleated cells and freely filtered by the glomerulus, serves as an alternative marker of GFR that is less affected by muscle mass and may provide a more accurate assessment in certain populations.

<image>Panel A: Basic metabolic panel components showing electrolytes (sodium, potassium, chloride, bicarbonate), renal function tests (BUN, creatinine), and glucose with normal ranges and clinical significance. Panel B: Comprehensive metabolic panel additional tests including calcium, total protein, albumin, bilirubin, and liver enzymes (AST, ALT, alkaline phosphatase) with normal values. Panel C: Liver injury patterns comparing hepatocellular pattern (markedly elevated AST/ALT with mild ALP increase) versus cholestatic pattern (markedly elevated ALP and bilirubin with mild transaminase increase) and AST:ALT ratio greater than 2 suggesting alcoholic liver disease. Panel D: Renal function assessment showing BUN/creatinine ratio interpretation (elevated in pre-renal, normal in intrinsic renal), eGFR calculation and staging of chronic kidney disease, and cystatin C as alternative marker.</image>

---

### IV. Urinalysis

The physical examination of urine provides immediate, readily available information that can guide clinical decision-making before more detailed analysis is complete. Normal urine color is yellow, resulting from the pigment urochrome, with intensity varying based on concentration; red or pink discoloration suggests hematuria or the presence of myoglobin, while brown urine may indicate conjugated bilirubinuria or oxidized hemoglobin. Clarity is normally clear, with cloudiness suggesting infection with white blood cells and bacteria, crystal precipitation, or lipiduria in nephrotic syndrome. Specific gravity, normally ranging from 1.005 to 1.030, reflects the kidney's concentrating ability and varies with hydration status; a fixed specific gravity at 1.010, the isosthenuric point, indicates loss of concentrating and diluting ability characteristic of advanced renal failure or renal tubular damage.

Urine dipstick testing provides a rapid, semi-quantitative assessment of multiple analytes through colorimetric reactions on impregnated reagent pads. Urine pH, normally ranging from 5 to 8, varies with diet and may be altered by urinary tract infections with urease-producing organisms that alkalinize the urine. Protein detection on dipstick primarily reflects albuminuria and, when positive, suggests glomerular disease that has disrupted the normal charge barrier preventing albumin filtration. Glucosuria indicates that serum glucose has exceeded the renal threshold for reabsorption, most commonly in diabetes mellitus. Blood detected by dipstick, which reacts with the peroxidase activity of hemoglobin, may indicate urinary tract infection, nephrolithiasis, or urinary tract tumors. Leukocyte esterase, an enzyme released by lysed neutrophils, serves as an indicator of pyuria and possible urinary tract infection. Nitrites, produced by bacterial reduction of dietary nitrate, indicate the presence of gram-negative bacteria in the urine and support a diagnosis of UTI. Ketones detected in urine indicate fat metabolism, occurring in diabetic ketoacidosis (DKA), starvation, and prolonged fasting. Bilirubin detected in urine indicates conjugated hyperbilirubinemia, since only water-soluble conjugated bilirubin is filtered by the glomerulus.

Microscopic examination of the urine sediment provides definitive identification of cellular elements, casts, crystals, and organisms that refine the clinical assessment. Red blood cells exceeding 3 per high-power field (HPF) are considered abnormal and may indicate glomerular disease, particularly when dysmorphic forms are present, or lower urinary tract pathology including stones, infection, and malignancy. White blood cells exceeding 5 per HPF suggest urinary tract infection or interstitial nephritis, and when associated with positive leukocyte esterase and nitrites, strongly support a diagnosis of bacterial UTI. The presence of urinary casts is particularly significant because casts form within the renal tubules and therefore indicate that the pathologic process originates within the kidney rather than the lower urinary tract. Bacteria visible on microscopy support the diagnosis of urinary tract infection, though contamination must be excluded. Crystals of various types may be identified, with some representing normal findings and others suggesting pathologic conditions.

Urinary casts provide invaluable diagnostic information because they are formed exclusively within the renal tubules, localizing the site of disease to the kidney. Hyaline casts are composed of Tamm-Horsfall mucoprotein alone and may be found in normal concentrated urine, representing a non-specific finding. Red blood cell casts, containing intact erythrocytes within a protein matrix, are essentially pathognomonic for glomerulonephritis and indicate that hematuria is of glomerular origin. White blood cell casts indicate renal parenchymal inflammation, most commonly pyelonephritis or acute interstitial nephritis, and distinguish upper from lower urinary tract infection. Granular casts, particularly the coarsely granular "muddy brown" variety, are characteristic of acute tubular necrosis and may also be found in chronic renal disease as a nonspecific indicator of tubular injury. Waxy casts are broad, homogeneous structures that represent the end stage of cast degeneration and indicate chronic renal failure with dilated, atrophic tubules. Fatty casts, containing lipid droplets that exhibit a Maltese cross pattern under polarized light, are associated with nephrotic syndrome and reflect the lipiduria that accompanies heavy proteinuria.

<image>Panel A: Urinalysis physical examination showing color variations (yellow normal, red suggesting blood, brown suggesting bilirubin), clarity (clear normal, cloudy suggesting infection or crystals), and specific gravity interpretation. Panel B: Urine dipstick testing with positive findings and clinical significance for pH, protein (glomerular disease), glucose (diabetes), blood (UTI, stones), leukocyte esterase and nitrites (UTI), ketones (DKA), and bilirubin. Panel C: Urine microscopy findings showing RBCs and WBCs with normal thresholds, bacteria suggesting infection, and various crystal types (calcium oxalate, uric acid, struvite) with clinical associations. Panel D: Urinary cast types and clinical correlations including hyaline (concentrated urine), RBC casts (glomerulonephritis), WBC casts (pyelonephritis), granular casts (ATN), waxy casts (chronic renal failure), and fatty casts (nephrotic syndrome).</image>

---

### V. Coagulation Testing

Primary hemostasis tests evaluate platelet number and function, assessing the initial response to vascular injury that produces the platelet plug. The platelet count, normally ranging from 150,000 to 400,000 per microliter, provides a quantitative assessment of platelet availability, with thrombocytopenia below this range increasing bleeding risk, particularly when counts fall below 50,000 for surgical hemostasis or below 10,000 for spontaneous bleeding. The bleeding time, historically used to assess platelet function in vivo by measuring the time for cessation of bleeding from a standardized skin incision, normally ranges from 2 to 9 minutes, though this test has largely been supplanted by newer methods. The Platelet Function Analyzer (PFA-100) provides an in vitro screening assessment of platelet function by measuring the time required for platelets to occlude an aperture in a membrane coated with collagen and either epinephrine or ADP, offering greater standardization and reproducibility than the bleeding time.

Secondary hemostasis tests evaluate the coagulation cascade, measuring the activity of clotting factors in the extrinsic, intrinsic, and common pathways. The prothrombin time (PT), normally 11 to 15 seconds, measures the extrinsic pathway by assessing factor VII activity along with the common pathway factors X, V, prothrombin, and fibrinogen, and is prolonged by warfarin therapy, liver disease, and vitamin K deficiency. The international normalized ratio (INR), normally 0.8 to 1.2, standardizes the PT across different laboratories and reagent systems by correcting for the sensitivity of the thromboplastin reagent, enabling consistent monitoring of warfarin anticoagulation. The partial thromboplastin time (PTT), normally 25 to 35 seconds, measures the intrinsic pathway by assessing factors VIII, IX, XI, and XII along with the common pathway, and is prolonged by heparin therapy and deficiencies of intrinsic pathway factors. The thrombin time, normally 14 to 19 seconds, specifically measures the final step of the coagulation cascade, the conversion of fibrinogen to fibrin by thrombin, and is prolonged by heparin, low fibrinogen, and the presence of fibrin degradation products.

Interpretation of coagulation results depends on recognizing characteristic patterns of PT and PTT abnormalities that localize the defect to specific pathways. An isolated prolonged PT with normal PTT indicates a defect in the extrinsic pathway, most commonly factor VII deficiency or early warfarin therapy when factor VII, with its shortest half-life, is the first to decline. A normal PT with isolated prolonged PTT points to the intrinsic pathway, including deficiencies of factors VIII (hemophilia A), IX (hemophilia B), XI, or XII, as well as the anticoagulant effect of unfractionated heparin. Prolongation of both PT and PTT indicates a defect in the common pathway involving factors X, V, prothrombin, or fibrinogen, or a process that simultaneously affects multiple pathways such as severe liver disease, disseminated intravascular coagulation (DIC), or supratherapeutic warfarin. When both PT and PTT are normal despite clinical bleeding, factor XIII deficiency should be considered, as this fibrin-stabilizing factor is not assessed by either test, as should mild factor deficiencies that fall above the sensitivity threshold of screening tests.

Specific factor tests and specialized coagulation assays provide additional diagnostic precision when screening tests are abnormal or clinical suspicion persists despite normal screening results. The mixing study is a critical next step when an elevated PTT is identified, performed by mixing patient plasma 1:1 with normal pooled plasma: correction of the PTT indicates a factor deficiency that is corrected by supplying the missing factor, while failure to correct indicates the presence of an inhibitor such as the lupus anticoagulant or a specific factor inhibitor that neutralizes the added factor. Individual factor assays quantify the activity of specific coagulation factors, enabling definitive diagnosis of hemophilia and other factor deficiencies. The fibrinogen level, normally 200 to 400 mg/dL, reflects both hepatic synthetic capacity and consumption in coagulation, with critically low levels seen in DIC and severe liver disease. D-dimer, a degradation product of cross-linked fibrin, serves as a marker of active fibrinolysis and is used to evaluate for deep venous thrombosis (DVT) and pulmonary embolism (PE), with a negative result effectively excluding venous thromboembolism in low-probability patients. Anti-factor Xa assays directly measure the anticoagulant effect of heparin and low-molecular-weight heparin, providing more accurate monitoring than the PTT in certain clinical situations.

<image>Panel A: Coagulation cascade diagram showing intrinsic pathway (factors XII, XI, IX, VIII measured by PTT) and extrinsic pathway (factor VII measured by PT/INR) converging on common pathway (factors X, V, prothrombin, fibrinogen). Panel B: Interpretation table for PT and PTT combinations showing isolated PT elevation (factor VII, early warfarin), isolated PTT elevation (factors VIII, IX, XI, XII, heparin), both elevated (common pathway, liver disease, DIC), and both normal (factor XIII, mild deficiency). Panel C: Mixing study interpretation showing correction with normal plasma indicating factor deficiency versus failure to correct indicating presence of inhibitor (lupus anticoagulant or specific factor inhibitor). Panel D: Specific coagulation tests including fibrinogen level, D-dimer for fibrinolysis and DVT/PE evaluation, anti-Xa for heparin monitoring, and factor assays for specific deficiencies.</image>

---

### VI. Cardiac Biomarkers

Cardiac troponins have revolutionized the diagnosis of myocardial infarction, serving as the biomarker of choice due to their exquisite cardiac specificity and sensitivity. Troponin I and troponin T are structural proteins of the cardiac contractile apparatus that are released into the circulation when myocardial cell membrane integrity is lost, making them highly cardiac-specific markers not significantly affected by skeletal muscle injury. Troponin levels begin to rise 3 to 6 hours after the onset of myocardial injury, reflecting the time required for intracellular troponin to leak through damaged cell membranes, diffuse through the interstitium, and enter the lymphatic drainage and bloodstream. Peak levels are reached at 12 to 24 hours, correlating with the maximum extent of myocardial necrosis. Troponin levels remain elevated for 7 to 14 days, providing a prolonged window for detection that is useful for diagnosing infarctions presenting days after symptom onset. High-sensitivity troponin assays can detect much lower concentrations of circulating troponin, enabling earlier detection of myocardial injury, often within 1 to 3 hours of symptom onset, and have transformed the diagnostic approach to acute coronary syndromes.

Other cardiac biomarkers complement troponin in the assessment of cardiac disease. Creatine kinase-MB (CK-MB), an isoenzyme found predominantly in cardiac muscle, was formerly the gold standard for MI diagnosis but is less specific than troponin and has largely been supplanted; however, its earlier return to baseline (48-72 hours) compared to troponin makes it useful for detecting reinfarction. B-type natriuretic peptide (BNP) and its inactive N-terminal fragment (NT-proBNP) are released by ventricular cardiomyocytes in response to myocardial wall stretch and volume overload, making them invaluable biomarkers for the diagnosis and monitoring of heart failure. Myoglobin, a small heme protein found in both cardiac and skeletal muscle, rises earliest of all cardiac markers, often within 1 to 3 hours of injury, but is non-specific for cardiac damage and has been largely replaced by high-sensitivity troponin assays.

Interpretation of cardiac biomarkers requires integration with the clinical presentation and recognition that elevations may occur in conditions other than acute myocardial infarction. In acute MI, troponin elevation with a rising and/or falling pattern in the appropriate clinical context establishes the diagnosis, while BNP levels are variable depending on the degree of myocardial dysfunction. In heart failure, troponin may be mildly elevated due to myocardial stretch and subendocardial ischemia, but BNP and NT-proBNP are characteristically markedly elevated and correlate with disease severity and prognosis. In renal failure, both troponin and BNP may be elevated due to decreased renal clearance and the cardiac effects of uremia, requiring adjusted cutoffs for clinical interpretation. In pulmonary embolism, right ventricular strain may produce troponin elevation reflecting right heart injury, while BNP elevation reflects the acute pressure overload on the right ventricle.

Serial troponin testing is essential for the accurate diagnosis of acute coronary syndromes, as a single measurement may miss early presentations and cannot distinguish acute from chronic elevation. A baseline measurement at presentation establishes the initial troponin level, which may be normal in patients presenting very early after symptom onset. A repeat measurement at 3 to 6 hours detects the rising pattern that characterizes acute myocardial injury, with a significant rise or fall (delta change) from baseline providing stronger diagnostic evidence than an isolated elevated value. The delta change from baseline, typically defined as a change exceeding the 99th percentile of a healthy reference population, helps distinguish acute myocardial injury with its dynamic pattern from chronic troponin elevation seen in stable conditions such as chronic kidney disease. With the advent of high-sensitivity troponin assays, rapid rule-out protocols using a single measurement or two measurements taken one hour apart may suffice in low-risk patients, significantly reducing emergency department length of stay.

<image>Panel A: Troponin kinetics graph showing rise beginning 3-6 hours after myocardial injury, peak at 12-24 hours, and return to baseline over 7-14 days, with high-sensitivity troponin enabling earlier detection. Panel B: Comparison of cardiac biomarkers showing troponin I and T as cardiac-specific with prolonged elevation, CK-MB with earlier clearance but less specificity, and myoglobin rising earliest but non-specific. Panel C: BNP and NT-proBNP interpretation for heart failure showing elevated levels with ventricular stretch, adjusted cutoffs for renal insufficiency, and correlation with disease severity and prognosis. Panel D: Acute coronary syndrome diagnostic algorithm incorporating serial troponin measurements at presentation and 3-6 hours, delta change criteria, and integration with clinical presentation and ECG findings.</image>

---

### VII. Serologic Testing

Serologic testing encompasses a range of laboratory methods that detect antibodies or antigens in patient serum, providing diagnostic information for autoimmune diseases, infections, and other immunologic conditions. The enzyme-linked immunosorbent assay (ELISA) is the most widely used serologic platform, operating on the principle of antibody-antigen binding coupled with enzyme-mediated colorimetric detection that allows both qualitative and quantitative assessment of analyte concentration. Immunofluorescence uses fluorescent-labeled antibodies to detect target antigens or patient antibodies in tissue sections or cell preparations, producing characteristic patterns that provide diagnostic specificity. Western blot separates proteins by molecular weight through gel electrophoresis and then probes with patient serum to detect antibodies against specific protein bands, serving as a confirmatory test with higher specificity than screening methods. Agglutination assays detect antibodies by their ability to cross-link particulate antigens, producing visible clumping that forms the basis of blood bank testing and rapid diagnostic assays.

Autoantibody testing plays a central role in the diagnosis and monitoring of autoimmune diseases. Antinuclear antibodies (ANA) represent the most commonly ordered autoimmune screening test, with positive results reported along with the immunofluorescence pattern that provides additional diagnostic information, though ANA positivity occurs in many autoimmune conditions and even in some healthy individuals. Anti-double-stranded DNA (anti-dsDNA) antibodies are relatively specific for SLE and correlate with disease activity, particularly lupus nephritis. Anti-Smith antibodies are highly specific for SLE though less sensitive than anti-dsDNA. Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific for rheumatoid arthritis and may precede clinical disease by years. Antineutrophil cytoplasmic antibodies (ANCA) are directed against neutrophil granule proteins and are associated with small vessel vasculitides, with the two patterns (c-ANCA/PR3 and p-ANCA/MPO) correlating with specific diseases. Anti-glomerular basement membrane (anti-GBM) antibodies targeting type IV collagen are diagnostic of Goodpasture syndrome.

Infectious serology relies on the detection of pathogen-specific antibodies whose immunoglobulin class and titer provide information about the timing and stage of infection. IgM antibodies are the first immunoglobulin class produced during an immune response and indicate an acute or recent infection, as they typically appear within the first week and decline over weeks to months. IgG antibodies develop later and persist long-term, indicating past infection or established immunity, and form the basis of immunity verification for vaccine-preventable diseases. Seroconversion, defined as the development of detectable antibodies or a four-fold rise in antibody titers between acute and convalescent sera drawn two to four weeks apart, provides definitive evidence of recent infection. IgG avidity testing, which measures the strength of antibody-antigen binding, helps distinguish recent from remote infection, as early IgG antibodies have low avidity that matures over months, a distinction particularly important in pregnancy for assessing the risk of congenital toxoplasmosis and CMV.

Hepatitis B serology exemplifies the complexity and clinical utility of infectious serologic testing, with multiple markers whose patterns define the stage of infection and immunity. Hepatitis B surface antigen (HBsAg) indicates active infection with circulating virus, present during both acute and chronic infection. Anti-hepatitis B surface antibody (anti-HBs) indicates immunity, whether acquired through vaccination (where it appears as the sole marker) or natural infection following viral clearance. Anti-hepatitis B core IgM (anti-HBc IgM) is the earliest antibody marker to appear and indicates acute infection, serving as the diagnostic test of choice during the window period when HBsAg has been cleared but anti-HBs has not yet appeared. Anti-hepatitis B core total (anti-HBc total) indicates past exposure to hepatitis B virus and remains positive for life. Hepatitis B e antigen (HBeAg) indicates a high level of viral replication and high infectivity, and its presence or absence in chronic HBV infection guides treatment decisions and prognostic assessment.

<image>Panel A: ELISA principle showing antigen coating on plate, patient antibody binding, enzyme-conjugated secondary antibody addition, substrate conversion producing color change proportional to antibody concentration. Panel B: Autoantibody testing patterns showing ANA screening with positive immunofluorescence patterns (homogeneous, speckled, nucleolar, centromere), disease-specific antibodies (anti-dsDNA for SLE, anti-CCP for RA, ANCA for vasculitis). Panel C: Infectious serology interpretation showing IgM indicating acute or recent infection, IgG indicating past infection or immunity, seroconversion with rising titers, and IgG avidity distinguishing recent from remote infection. Panel D: Hepatitis B serology interpretation table showing acute infection (HBsAg+, anti-HBc IgM+), chronic infection (HBsAg+, anti-HBc total+), immunity from vaccination (anti-HBs+ only), and immunity from natural infection (anti-HBs+, anti-HBc+).</image>

---

### VIII. Molecular Diagnostics

Nucleic acid amplification techniques, led by the polymerase chain reaction (PCR), have transformed diagnostic medicine by enabling the detection and quantification of specific DNA and RNA sequences with extraordinary sensitivity. Standard PCR amplifies specific DNA sequences through repeated cycles of denaturation, primer annealing, and polymerase-mediated extension, producing millions of copies from a single target molecule to enable detection of pathogens, mutations, and genetic variants. Reverse transcription PCR (RT-PCR) adds an initial step in which reverse transcriptase converts RNA to complementary DNA, enabling detection of RNA viruses such as SARS-CoV-2 and HIV, as well as measurement of HIV viral load for treatment monitoring. Real-time PCR (quantitative PCR) incorporates fluorescent probes or dyes that emit signal proportional to the amount of amplified product during each cycle, enabling quantification of the initial target concentration and forming the basis of viral load testing for HIV, hepatitis C, and other chronic viral infections. Multiplex PCR simultaneously amplifies multiple targets in a single reaction using multiple primer pairs, enabling comprehensive syndromic panels that test for dozens of pathogens from a single respiratory, gastrointestinal, or cerebrospinal fluid specimen.

Sequencing technologies provide the ultimate resolution in molecular diagnostics by determining the precise nucleotide order of DNA or RNA molecules. Sanger sequencing, developed in the 1970s and remaining the gold standard for targeted single-gene analysis, uses chain-terminating dideoxynucleotides to generate fragments of varying lengths that are separated by electrophoresis, providing reliable sequences of up to approximately 1,000 base pairs. Next-generation sequencing (NGS) represents a revolutionary advance that performs massively parallel sequencing of millions of DNA fragments simultaneously, enabling whole exome sequencing of all coding regions, whole genome sequencing, and targeted gene panels at dramatically reduced cost and turnaround time compared to traditional methods. Whole exome sequencing captures and sequences approximately 1-2% of the genome representing all protein-coding regions, proving particularly powerful for identifying the genetic basis of rare diseases and cancer mutations. RNA sequencing (RNA-seq) provides a comprehensive assessment of gene expression by sequencing the entire transcriptome, identifying which genes are active and at what levels in a given tissue, with applications in cancer classification and pharmacogenomics.

The clinical applications of molecular diagnostics span virtually every area of medicine, with particularly transformative impact in infectious disease and oncology. In infectious disease, PCR and RT-PCR enable rapid, highly sensitive detection of pathogens including HIV viral load monitoring, hepatitis C virus quantification to assess treatment response, Mycobacterium tuberculosis identification directly from clinical specimens, and SARS-CoV-2 diagnosis. In oncology, molecular testing identifies therapeutically actionable mutations such as the BCR-ABL fusion gene in chronic myeloid leukemia that is targeted by imatinib, and EGFR mutations in non-small cell lung cancer that predict response to tyrosine kinase inhibitors. Pharmacogenomics uses molecular testing to identify genetic variants in drug-metabolizing enzymes, such as CYP2D6 and CYP2C19 polymorphisms, that predict individual responses to specific medications and guide dosing decisions. Genetic diagnosis of inherited diseases, from single-gene disorders identified by targeted testing to complex genetic conditions requiring comprehensive genomic analysis, has become a cornerstone of modern clinical genetics and prenatal diagnosis.

Point-of-care testing (POCT) brings laboratory analysis to the patient's bedside, offering significant advantages in clinical settings where rapid results can directly influence immediate management decisions. The primary advantages include rapid availability of results, often within minutes, that can guide real-time clinical decisions in emergency departments, operating rooms, and intensive care units. Bedside testing eliminates specimen transport delays and reduces turnaround time compared to central laboratory analysis. The elimination of specimen transport also reduces pre-analytical variables associated with handling and processing delays. Timely results from point-of-care testing enable faster clinical decision-making in time-sensitive conditions such as acute coronary syndromes, diabetic emergencies, and acid-base disturbances. However, limitations include variable analytical quality compared to central laboratory instruments, a limited test menu that cannot replace the comprehensive capabilities of a full clinical laboratory, operator dependence with potential for user error in non-laboratory personnel, and documentation challenges in maintaining proper result recording and quality control oversight.

<image>Panel A: PCR principle showing DNA denaturation, primer annealing to target sequence, and polymerase extension, with exponential amplification through repeated cycles enabling detection of specific sequences. Panel B: Real-time PCR and RT-PCR showing fluorescent probe detection during amplification for quantification (viral load testing), and reverse transcriptase step for RNA virus detection (COVID-19, HIV, HCV). Panel C: Next-generation sequencing workflow from DNA extraction through library preparation, massively parallel sequencing, and bioinformatic analysis for targeted panels, whole exome, or whole genome applications. Panel D: Clinical applications of molecular diagnostics including infectious disease (pathogen detection and resistance genes), oncology (BCR-ABL, EGFR mutations for targeted therapy), pharmacogenomics (drug metabolism variants), and genetic diagnosis of inherited conditions.</image>

---

### IX. Blood Banking

ABO and Rh blood group typing represents the most critical pre-transfusion test, as ABO incompatibility can produce fatal hemolytic transfusion reactions within minutes. Forward typing determines the antigens present on the patient's red blood cells by mixing them with known anti-A and anti-B antisera and observing for agglutination, with the pattern of reactivity defining the patient's blood type as A, B, AB, or O. Reverse typing confirms the forward type by testing the patient's serum against known type A and type B red blood cells, exploiting the fact that individuals naturally produce antibodies against ABO antigens they lack. Rh typing determines the presence or absence of the D antigen, the most immunogenic of the Rh antigens, using anti-D reagent, with D-positive individuals classified as Rh positive and D-negative as Rh negative. Extended or weak D testing may be performed when initial D typing is equivocal, using the indirect antiglobulin test to detect weak expression of the D antigen.

Compatibility testing ensures that transfused blood will not provoke a hemolytic reaction by detecting unexpected antibodies and confirming donor-recipient compatibility. The antibody screen, also known as the indirect antiglobulin test, mixes patient serum with a panel of reagent red blood cells expressing clinically significant antigens to detect unexpected alloantibodies that may have developed from prior transfusions or pregnancies. The crossmatch represents the final compatibility check before transfusion, mixing patient serum directly with donor red blood cells to confirm the absence of a serologic reaction. Electronic crossmatch, a computer-based verification of ABO compatibility, may be used in place of serologic crossmatch when the antibody screen is negative and the patient has no history of clinically significant antibodies, reducing turnaround time. The antiglobulin (Coombs) test is the most sensitive method for detecting antibody-antigen reactions on red blood cell surfaces and forms the basis of the direct antiglobulin test for autoimmune hemolytic anemia and the indirect test used in antibody screening and crossmatching.

Blood components are prepared from donated whole blood or collected by apheresis, with each component serving specific clinical indications. Packed red blood cells (PRBCs), the most commonly transfused blood component, are indicated for symptomatic anemia and acute blood loss, providing oxygen-carrying capacity without the volume overload associated with whole blood. Platelet concentrates are indicated for thrombocytopenia or platelet dysfunction with active bleeding or prior to invasive procedures, whether prepared from pooled random donor units or collected by single-donor apheresis. Fresh frozen plasma (FFP) contains all coagulation factors and is indicated for multiple factor deficiencies as seen in liver disease, DIC, warfarin reversal, and massive transfusion protocols. Cryoprecipitate, prepared by thawing FFP at controlled temperatures and recovering the precipitate, is enriched in fibrinogen, factor VIII, von Willebrand factor, and factor XIII, making it the treatment of choice for hypofibrinogenemia and an adjunctive source of factor VIII.

Transfusion reactions represent adverse events that may occur during or after blood product administration, ranging from benign to immediately life-threatening. Acute hemolytic transfusion reactions, the most feared complication, result from ABO incompatibility causing complement-mediated intravascular hemolysis of transfused red blood cells, presenting with fever, hypotension, flank pain, hemoglobinuria, and potentially disseminated intravascular coagulation and renal failure. Febrile non-hemolytic transfusion reactions, the most common transfusion reaction, result from cytokines accumulated in stored blood products or recipient antibodies against donor leukocyte antigens, producing fever and chills that resolve with antipyretics and leukoreduction of future transfusions. Allergic transfusion reactions range from mild urticaria, manageable with antihistamines, to severe anaphylaxis particularly in IgA-deficient patients who have developed anti-IgA antibodies. Transfusion-related acute lung injury (TRALI) is a potentially fatal complication in which donor antibodies against recipient leukocyte antigens activate neutrophils in the pulmonary vasculature, producing bilateral pulmonary infiltrates and respiratory failure within 6 hours of transfusion.

<image>Panel A: ABO blood typing showing forward typing with patient RBCs and known anti-A and anti-B antisera, reverse typing with patient serum and known A and B cells, and Rh typing with anti-D reagent. Panel B: Compatibility testing workflow including antibody screen to detect unexpected antibodies, antibody identification if screen positive, and crossmatch as final compatibility check before transfusion. Panel C: Blood components and indications showing packed RBCs for anemia and blood loss, platelets for thrombocytopenia or dysfunction, FFP for multiple factor deficiency, and cryoprecipitate for fibrinogen and factor VIII. Panel D: Transfusion reactions comparing acute hemolytic (ABO incompatibility with fever, hypotension, hemoglobinuria), febrile non-hemolytic (cytokines causing fever and chills), allergic (urticaria to anaphylaxis), and TRALI (lung injury with bilateral infiltrates within 6 hours).</image>

---

### X. Microbiology Laboratory

Specimen processing in the microbiology laboratory follows a systematic workflow that begins with rapid preliminary assessments and proceeds to definitive identification and susceptibility testing. The Gram stain is the most important rapid diagnostic tool in microbiology, providing immediate information about the morphology and staining characteristics of organisms present in clinical specimens, distinguishing gram-positive cocci in clusters (staphylococci) and chains (streptococci) from gram-negative rods and diplococci. Culture on appropriate media allows organisms to grow and form colonies whose characteristics, combined with biochemical testing, enable definitive identification, typically requiring 24 to 48 hours for most routine bacterial pathogens. Antimicrobial sensitivity testing determines which antibiotics are effective against the isolated organism, guiding targeted therapy. Automated systems and newer technologies including matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) and molecular methods have dramatically accelerated organism identification, reducing turnaround time from days to hours.

Culture interpretation requires careful assessment of the clinical significance of isolated organisms, distinguishing true pathogens from contaminants and normal flora. The isolation of a single organism from a normally sterile site, such as blood or cerebrospinal fluid, is strong evidence that the organism is a true pathogen. Multiple organisms growing from a wound or sputum culture may represent either polymicrobial infection, which is common in abdominal and aspiration infections, or contamination with normal flora, requiring clinical correlation to determine significance. Normal flora isolated from sites where commensal organisms are expected, such as mixed oral flora from a sputum culture, may not require specific antimicrobial treatment and must be interpreted in context. Fastidious organisms, including Neisseria gonorrhoeae, Haemophilus influenzae, and anaerobes, require special culture media such as chocolate agar, Thayer-Martin agar, or anaerobic conditions for growth, and failure to use appropriate media may result in false-negative cultures.

Antimicrobial susceptibility testing determines whether an isolated organism is susceptible, intermediate, or resistant to specific antibiotics, directly guiding therapeutic selection. The minimum inhibitory concentration (MIC) is the gold standard, defined as the lowest concentration of an antibiotic that prevents visible bacterial growth, and is determined by serial dilution methods. Disk diffusion (Kirby-Bauer method) measures the zone of inhibition, the clear area surrounding an antibiotic-impregnated disk placed on an agar plate inoculated with the test organism, with larger zones indicating greater susceptibility. Breakpoints established by standardizing organizations define the MIC or zone size cutoffs that categorize organisms as susceptible (S), intermediate (I), or resistant (R), guiding clinical interpretation. Specific resistance patterns requiring detection include extended-spectrum beta-lactamases (ESBLs) in gram-negative organisms that confer resistance to most cephalosporins, and methicillin-resistant Staphylococcus aureus (MRSA) carrying the mecA gene.

Molecular microbiology has emerged as an essential complement to traditional culture-based methods, offering speed and sensitivity advantages that are particularly valuable for difficult-to-culture organisms and urgent clinical situations. PCR enables rapid detection of specific pathogens directly from clinical specimens without the delay of culture, with results available in hours rather than days. 16S ribosomal RNA gene sequencing provides definitive identification of bacterial species, including unusual and difficult-to-identify organisms, by comparing the sequence of this universally conserved gene against reference databases. Multiplex molecular panels now enable simultaneous testing for dozens of pathogens from a single specimen, with panels available for respiratory infections, gastrointestinal infections, and meningitis/encephalitis, providing comprehensive pathogen identification within hours. Molecular detection of resistance genes, including mecA for methicillin resistance in staphylococci and vanA for vancomycin resistance in enterococci, enables rapid identification of resistant organisms that guides infection control measures and empiric antibiotic selection before culture results are available.

<image>Panel A: Gram stain technique and interpretation showing gram-positive organisms (purple/blue, thick peptidoglycan) including cocci in clusters (Staph) and chains (Strep), and gram-negative organisms (pink/red, thin peptidoglycan) including rods (E. coli, Pseudomonas) and diplococci (Neisseria). Panel B: Culture plate interpretation showing single organism growth suggesting pathogen, mixed flora suggesting contamination or polymicrobial infection, and selective media for specific organisms (MacConkey, chocolate agar, Sabouraud). Panel C: Antimicrobial susceptibility testing with minimum inhibitory concentration (MIC) determination, disk diffusion with zone of inhibition measurement, and interpretation as susceptible, intermediate, or resistant based on breakpoints. Panel D: Molecular microbiology methods including PCR for rapid pathogen detection, 16S rRNA sequencing for identification, multiplex panels for syndromic testing (respiratory, GI, meningitis), and resistance gene detection (mecA for MRSA, vanA for VRE).</image>

---

## Summary

- Test characteristics: sensitivity, specificity, PPV, NPV
- CBC: RBC indices (MCV, MCH, MCHC), WBC differential, smear
- Chemistry: BMP (electrolytes, BUN, Cr), CMP (liver, albumin)
- Liver patterns: hepatocellular (AST/ALT), cholestatic (alk phos)
- Urinalysis: dipstick, microscopy, casts indicate renal origin
- Coagulation: PT (extrinsic), PTT (intrinsic), mixing studies
- Cardiac: troponin (MI), BNP (heart failure)
- Serology: IgM (acute), IgG (past), autoantibodies
- Molecular: PCR, NGS, sequencing; infectious and oncology
- Blood bank: ABO/Rh, crossmatch, transfusion reactions

---

## Key Terms

| Term | Definition |
|------|------------|
| Sensitivity | Ability to detect true positives |
| Specificity | Ability to identify true negatives |
| MCV | Mean corpuscular volume; RBC size |
| INR | International normalized ratio; standardized PT |
| Troponin | Cardiac-specific marker |
| ELISA | Enzyme-linked immunosorbent assay |
| PCR | Polymerase chain reaction |
| Crossmatch | Final compatibility test before transfusion |

---

*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*